25-26 August, 2011
Bangalore, India

Host: St. John's Research Institute, Bangalore, India
Sponsors: McGill University & Global Health Strategies
Technical partners: Bill & Melinda Gates Foundation, Foundation for Innovative New Diagnostics, International Centre for Genetic Engineering and Biotechnology (ICGEB), India & Stop TB Partnership
Industry partners: Association of Biotechnology Led Enterprises (ABLE) & Confederation of Indian Industry (CII)
Media partners: BioSpectrum Asia, Express Pharma & Express Healthcare

The scale up of DOTS in India is a great public health accomplishment, and yet undiagnosed and poorly managed TB continues to fuel the epidemic. Recognizing these challenges, the Government of India has set an ambitious goal of providing universal access to quality diagnosis and treatment for all TB patients. Innovative tools and delivery systems in both the public and private sectors are critical for reaching this goal. The current in-vitro diagnostics market in India is dominated by imported and generic products, with virtually no innovations. But India has the potential to solve its TB problem with "home-grown" solutions. Just as Indian pharma and biotech companies revolutionized access to high-quality, affordable AIDS drugs and hepatitis vaccines through generic production, Indian diagnostic companies could also become the world's hub for high-quality generic diagnostics. India also has the potential to lead the world in developing innovative TB diagnostics. For this to happen, Indian industry must move from the import and imitation approach to genuine innovation in both product development as well as delivery. This will require permissive policies, enhanced funding, and collaboration between government, donors, researchers and the private industry. The goal of this conference is to engage these stakeholders to stimulate interest and investments in TB innovations.


Conference Agenda [Download]

Conference Participants

List of Conference Participants [Download]


25 August 2011

Lucica Ditiu
Executive Secretary, Stop TB Partnership, Geneva
Industry – a key partner in TB control

Nachiket Mor
Director, IKP Centre for Technologies in Public Health & Chair, Sughavazhvu Healthcare
Innovative technologies need to be delivered innovatively to make an impact

Peter Small
Deputy Director, TB, Bill & Melinda Gates Foundation
Innovations in TB: India must take the lead

KS Sachdeva
RNTCP, Central TB Division, Ministry of Health and Family Welfare
TB in India: burden, progress, and needs

Mark Perkins
Foundation for Innovative New Diagnostics, Geneva
TB diagnosis in 2011: state of the art

Ajay Bakshi
McKinsey & Company
What is the business case for investing in TB diagnostics in India?

Chris Dye
World Health Organization, Geneva
What can India achieve with improved TB diagnosis?

Rishi Krishnan
Indian Institute of Management, Bangalore
Overcoming barriers to innovations in India

Chandrasekhar Nair
Bigtec Labs, Bangalore
Biotech companies in India: what will get them interested in TB?

Peter Small
Deputy Director, TB, Bill & Melinda Gates Foundation
Funding for TB innovations in India

Jay Menon
X Prize Foundation
Prizes - a way to spur TB innovations in India?

26 August 2011

Jasjit Mangat
Omidyar Network
Venture capital investments in TB innovations: risks and opportunities

VS Chauhan
International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi
Improving academia-industry partnerships

John Kenneth
St. John's Research Institute, Bangalore
Improving quality, regulation, and market dynamics

Puneet Dewan
World Health Organization, SEARO, New Delhi
Engaging private sector for delivery innovations

Dinesh Puri
MediVed, Bangalore
Frugal innovation in BRICS: hype or hope?

Javid Syed
reatment Action Group (TAG)
Engaging media and civil society to support TB innovations

Videos (work in progress)

25 August 2011

August 25 - Morning - Part I [Download]
August 25 - Morning - Part II [Download]
August 25 - Morning - Part III [Download]
August 25 - Morning - Part IV [Download]
August 25 - Morning - Part V [Download]
August 25 - Morning - Part VI [Download]
August 25 - Morning - Part VII [Download]
August 25 - Morning - Part VIII [Download]
August 25 - Morning - Part IX [Download]
August 25 - Morning - Part X [Download]
August 25 - Morning - Part XI [Download]
August 25 - Morning - Part XII [Download]
August 25 - Morning - Part XIII [Download]

August 25 - Afternoon - Part I [Download]
August 25 - Afternoon - Part II [Download]
August 25 - Afternoon - Part III [Download]
August 25 - Afternoon - Part IV [Download]
August 25 - Afternoon - Part V [Download]
August 25 - Afternoon - Part VI [Download]
August 25 - Afternoon - Part VII [Download]
August 25 - Afternoon - Part VIII [Download]
August 25 - Afternoon - Part IX [Download]
August 25 - Afternoon - Part X [Download]

26 August 2011

August 26 - Morning - Part I [Download]
August 26 - Morning - Part II [Download]
August 26 - Morning - Part III [Download]
August 26 - Morning - Part IV [Download]
August 26 - Morning - Part V [Download]
August 26 - Morning - Part VI [Download]
August 26 - Morning - Part VII [Download]
August 26 - Morning - Part VIII [Download]

August 26 - Afternoon - Part I [Download]
August 26 - Afternoon - Part II [Download]
August 26 - Afternoon - Part III [Download]
August 26 - Afternoon - Part IV [Download]
August 26 - Afternoon - Part V [Download]
August 26 - Afternoon - Part VI [Download]
August 26 - Afternoon - Part VII [Download]
August 26 - Afternoon - Part VIII [Download]
August 26 - Afternoon - Part IX [Download]


Photo gallery: [Link]
Nature News Q&A; about the conference: [Link]

Sponsors and Partners

Last Updated: 1 October 2011

Close Window

Share |